SYSalih Abdella Yusuf

Salih Abdella Yusuf

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Salih Abdella Yusuf has a total of 127 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Ultrasound-guided versus fluoroscopy-guided shockwave lithotripsy for the treatment of renal and ureteric stones in the pediatric population: a systematic review and meta-analysis

    byĀ Hajar S. Almutairi, Rayan S. Alsaud, Ibrahim A. Almohaimeed, Faris H. Alneghimshi, Muhannad R. Alrubaysh, Reema A. Alhoushani, Mansour A. Albarrak, Khalid S. Alrashdi, Khaled M. Almoutairi, Abdullah A. Alharbi, et al.

  • Open Access

    Updated evidence on efficacy and safety of ondansetron compared with placebo for acute gastroenteritis-associated vomiting in children: a systematic review and meta-analysis of randomized controlled trials

    byĀ Bader S. Althunayyan, Reema A. Alhoushani, Leen M. Alhesayani, Sultan A. Alsallal, Lama N. Aldakhil, Sadeen J. Alharbi, Majd M. Alharbi, Yousef J. Aldaher, Yasser S. Aljumah, Wojoud A. Alharbi, et al.

  • Open Access

    Trends in diabetes and stroke-related mortality in the United States, 1999–2024: a population-based analysis

    byĀ Irfan Majeed, Haimath Kumar, Karan Kumar, Nikeeta Bai, Fnu Rajesh, Sunesh Kumar, Fnu Saneha, Hibba Aziz, Fnu Simran, Soni Rani, et al.

    Introduction: Stroke remains a leading cause of cardiovascular mortality and disability in the United States, with diabetes serving as a major comorbidity that exacerbates outcomes and economic burden. Individuals affected by both diabetes and stroke experience heightened risks of death, disability, and healthcare utilization. This study examines national trends in diabetes and stroke-related mortality from 1999 to 2024, stratified by demographic and geographic factors. Methods: Mortality data were extracted from the Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research Multiple Cause of Death database. Deaths were identified using International Classification of Diseases, 10th Revision codes for diabetes mellitus and stroke, defined as deaths in which both conditions were listed on the death certificate, either as underlying or contributing causes. Both crude and age-adjusted mortality rates (AAMRs) per 100 000 were calculated, standardized to the 2000 US population. Temporal patterns were assessed using Joinpoint regression to estimate annual percent change with 95% confidence intervals. Analyses were further stratified by age, sex, race, ethnicity, urbanization, and census region. Results: Between 1999 and 2024, 617 059 deaths were attributed to the combined burden of diabetes and stroke. National AAMR declined from 10.4 to 7.0 per 100 000, showing significant decreases until 2018, followed by an increase during 2018–2021 and subsequent decline through 2024. Mortality remained higher among men, non-Hispanic Black individuals, rural populations, and residents of Southern states. Conclusion: Although long-term mortality declined, recent reversals and enduring disparities emphasize the urgent need for integrated prevention and equitable public health strategies.


  • Open Access

    Efficacy and safety of SGLT2 inhibitor empagliflozin in T2DM with established cardiovascular disease: a systematic review and meta-analysis of RCTs

    byĀ Omar Abunada, Farhad Hassan, Naresh Kumar, Sunil Kumar, Irfan Majeed, Kantesh Batra, Dheeraj Kumar, Deepika Deepika, Muskan Turesh, Taimoor Ashraf, et al.

    Introduction: Effective treatment approaches are required for type 2 diabetes mellitus (T2DM) and cardiovascular diseases (CVDs) because these two diseases pose a big health issue for humans. Various medications, but with limitations in their efficacy, are available for the treatment of the above-mentioned diseases, but a drug, empagliflozin, a sodium–glucose cotransporter-2 inhibitor, has shown promising benefits for patients with T2DM and CVD, highlighting the need for a thorough review of its efficacy and safety. Methods: We searched online databases till 30 June 2024, and a total of 15 trials involving 8296 participants were included in this study. Evaluating the changes in HbA1c was a main concern of our study, while weight-related metrics [such as body weight and Body Mass Index (BMI)], cardiovascular indicators [like systolic blood pressure (SBP), diastolic blood pressure (DBP), changes in left ventricular ejection fraction %, and heart rate], and various laboratory values [including fasting plasma glucose (FPG), C-reactive protein (CRP), hematocrit, estimated glomerular filtration rate] were considered as secondary assessments. Results: Our study concluded that empagliflozin significantly reduced HbA1c levels [standardized mean difference (SMD) = āˆ’0.62, 95% CI = āˆ’0.95 to āˆ’0.30, I 2 = 85%, P = 0.0001], indicating improved glycemic control. Additionally, a reduction in body weight was also noted (SMD = āˆ’2.32, 95% CI = āˆ’3.42 to āˆ’1.21, I 2 = 54%, P < 0.0001). The drug also demonstrated favorable outcomes for secondary endpoints. Meta-regression and subgroup analyses provided insights into the variability of treatment effects across different populations. Conclusions: The efficacy of empagliflozin in managing T2DM and CVD is evaluated by this pooled analysis, highlighting great improvement in glycemic control and weight reduction. Further research is needed for empagliflozin’s long-term safety and efficacy across populations.


  • Open Access

    Evaluating mortality burden of diabetes mellitus and peripheral arterial disease in the United States: insights from 26 years of national data

    byĀ Ghazi Uddin Ahmed, Usha Kumari, Yogita Kumari, Soni Rani, Beesham Kumar Lohana, Akshy Kumar, Aniket Tara, Sahil Raj, Payal Kumari, Nikeeta Bai, et al.

    Background: Diabetes mellitus (DM) and peripheral arterial disease (PAD) are major contributors to mortality across the United States. Monitoring long-term mortality trends and demographic disparities is essential for guiding public health strategies aimed at high-risk populations. Methods: This retrospective analysis utilized mortality data from the CDC Wide-Ranging Online Data for Epidemiologic Research (CDC WONDER) database, covering the years 1999 through 2024. Deaths in which DM (ICD-10: E10–E14, O24, P70.2) and PAD (ICD-10: I70–I78) were documented as either primary or contributing causes were included. Age-adjusted mortality rates (AAMRs) per 100 000 people were calculated and stratified by year, gender, race/ethnicity, state, and urban-rural classification. Joinpoint regression analysis was used to identify significant changes in AAMR trends, quantified as annual percent changes. Results: A total of 274 117 deaths among individuals aged 15 and older were linked to both DM and PAD. Nationally, AAMR decreased from 4.3 in 1999 to 2.2 in 2024. Men consistently had higher AAMRs (3.9) than women (2.5). Among racial/ethnic groups, non-Hispanic American Indian or Alaska Native populations had the highest mortality rate (5.2). States such as West Virginia, Oklahoma, California, Vermont, and Ohio had the greatest AAMRs. Rural (nonmetropolitan) areas had higher rates (3.6) than metropolitan regions (3.0). Conclusions: Despite overall reductions in mortality, disparities by sex, race/ethnicity, and geography persist. The objective of this study was to explicitly assess long-term mortality trends and demographic disparities associated with DM and PAD in the United States, providing evidence to guide future preventive and policy measures. These results underscore the importance of targeted and equity-driven health interventions to reduce the burden of DM and PAD nationwide.


  • Open Access

    Clazosentan for cerebral vasospasm prevention in aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis

    byĀ Saaed Abunada, Taimoor Ashraf, Dinesh Kumar, Hasnain Ali Moryani, Partab Rai, Sumiya Abbasi, Nisha Devi, Muskan Turesh, Shah Dev, Salman Hyder, et al.

    Aneurysmal subarachnoid hemorrhage (aSAH) remains a devastating neurological emergency, with cerebral vasospasm contributing significantly to poor outcomes. Clazosentan, a selective endothelin-A receptor antagonist, has shown potential in preventing vasospasm, though its overall efficacy and safety profile require comprehensive assessment. We conducted a systematic review and meta-analysis following PRISMA guidelines, searching multiple databases through March 2025. We included randomized controlled trials and observational studies comparing clazosentan with placebo or active controls in aSAH patients. Outcomes included vasospasm incidence, its complications, and adverse events. Analysis of 13 reports (n = 5,728) were included. Compared to placebo, clazosentan significantly reduced vasospasm-related cerebral infarcts (RR: 0.56, p = 0.0002), delayed ischemic neurological deficits (DIND) (RR: 0.67, p < 0.0001), and the incidence of vasospasm (RR: 0.54, p < 0.00001). Compared to fasudil, clazosentan was associated with a lower incidence of vasospasm (RR: 0.44, p = 0.0004) and vasospasm-related cerebral infarcts (RR: 0.27, p = 0.002), but no significant difference was observed in DIND (p = 0.89). The drug showed particular benefit at higher doses (10–15 mg/h) and in surgical clipping patients. Clazosentan use was linked to a higher risk of adverse events, including pulmonary complications and hypotension (p < 0.05). While clazosentan effectively prevents cerebral vasospasm following aSAH, particularly at higher doses in surgically treated patients, its clinical utility must be weighed against significant systemic adverse effects. These findings support selective use in high-risk patients while highlighting the need for careful monitoring and individualized treatment approaches.


  • Open Access

    Correction: The role of Seladelpar in primary biliary cholangitis: a systematic review and meta-analysis

    byĀ Taimoor Ashraf, Omar Abunada, Nandlal Seerani, Kashif Ali, Areej Muhammad, Syeda Lamiya Mir, Syed Adil Mir Shah, Muhammad Hassaan, Vikash Kumar, Waseem Abbas, et al.


  • Open Access

    The impact of olezarsen on hypertriglyceridemia in high cardiovascular risk patients: a systematic review, meta-analysis, and meta-regression

    byĀ Taimoor Mbbs Ashraf, Nisha Mbbs Devi, Fnu Mbbs Aradhna, Sanjana Mbbs Devi, Fnu Mbbs Nancy, Avinash Mbbs Kumar, Fiza Mbbs Ameer, Laksh Mbbs Kumar, Sateesh Mbbs Kumar, Maheen Mbbs Jabbar, et al.

    Background and objective: Hypertriglyceridemia is a prevalent lipid disorder that considerably increases the risk of cardiovascular diseases, pancreatitis, and metabolic syndrome. Existing treatment options, including lifestyle changes and medications, often show limited effectiveness and may cause side effects. Olezarsen, an antisense oligonucleotide targeting apolipoprotein C-III (apoC-III), represents a novel therapeutic strategy for lowering triglyceride levels. This systematic review and meta-analysis assess the efficacy and safety of olezarsen in comparison to a placebo for managing hypertriglyceridemia. Methods: A systematic literature search was performed in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines across databases such as PubMed, Google Scholar, and the Cochrane Library, incorporating clinical trials and conference proceedings. Studies that compared olezarsen with a placebo and reported outcomes related to triglyceride levels, apoC-III, and other lipid parameters were included. Two independent reviewers conducted data extraction and quality assessment. Statistical analyses were performed using RevMan, employing risk ratios for dichotomous variables and standard mean differences for continuous variables, with a random-effects model. Results: Three randomized controlled trials, comprising 334 participants, were included in the analysis. Olezarsen significantly lowered triglyceride levels at both 6 months (standard mean difference [SMD]: -1.69, 95% CI -2.22 to -1.17) and 12 months (SMD: -1.64, 95% CI -2.22 to -1.07). Very low-density lipoprotein (VLDL) levels also declined at 6 months (SMD: -1.95, 95% CI -2.38 to -1.51) and 12 months (SMD: -0.83, 95% CI -1.13 to -0.53). Additional lipid profile improvements included reductions in total cholesterol, non-HDL cholesterol, and apoB levels, along with increases in HDL cholesterol and apoA-1. The incidence of adverse events was similar between the olezarsen and placebo groups. Conclusion: Olezarsen effectively reduces triglyceride and VLDL levels while enhancing lipid profiles in patients with hypertriglyceridemia. Although serious adverse events were more frequent, the overall safety profile remains acceptable. Further long-term research is required to validate these findings and optimize treatment regimens.


  • Open Access

    Continuous Glucose Monitoring and Hypoglycaemia Metrics With Once‐Weekly Basal Insulin Fc Versus Insulin Degludec: A Systematic Review and Meta‐Analysis

    byĀ Saaed Abunada, Sheela Bai, Usha Kumari, F. N. U. Nancy, Areeba Khan, Nikeeta Bai, F. N. U. Shevani, Anusha Bai, Shah Dev, Noshad Zain Ul Abiddin, et al.

    Introduction: Once‐weekly basal insulin Fc (BIF) offers a promising alternative to daily basal insulin by reducing injection burden while maintaining glycaemic control. However, comprehensive comparisons with insulin degludec regarding continuous glucose monitoring (CGM) metrics and hypoglycaemia outcomes remain limited. This meta‐analysis evaluates these critical parameters.Methods: We conducted a systematic review and meta‐analysis of randomised controlled trials (RCTs) comparing once‐weekly BIF with once‐daily insulin degludec in type 1 and type 2 diabetes. Outcomes included CGM‐derived glycaemic variability, time in range, time above/below range and hypoglycaemia event rates. Data were pooled using random‐effects models, with heterogeneity assessed via I2 statistics.Results: Five RCTs (n = 2427) were included. BIF demonstrated comparable glycaemic variability (within‐day CV: MD = 0.06, p = 0.90; between‐day CV: MD = ‐0.26, p = 0.30) and Time in range (MD = 0.56, p = 0.27) versus degludec. However, BIF increased time spent in the mild hypoglycaemia range (54–69 mg/dL) (MD = 0.30, p = 0.0004) and clinically significant hypoglycaemia event rates (rate ratio = 1.20, p < 0.00001). Severe hypoglycaemia event rates were higher with BIF (rate ratio = 3.34, p < 0.0001). Nocturnal hypoglycaemia and time above range (> 250 mg/dL) did not differ significantly.Conclusion: Once‐weekly BIF provides similar overall glycaemic control to insulin degludec but with increased time in mild hypoglycaemia and higher event rates of clinically significant and severe hypoglycaemia. These findings highlight the need for individualised dosing and monitoring when transitioning to weekly insulin regimens.


  • Open Access

    Once-weekly insulin icodec vs. daily insulin glargine in type 2 diabetes: a meta-analysis with longitudinal insights

    byĀ Taimoor Ashraf, Akshy Kumar, Aniket Tara, Naila Memon, Areej Muhammad, Muskan Turesh, Shah Dev, Noor Muhammad, Vikash Kumar, Tooba Hussain, et al.

    Introduction: Type 2 diabetes mellitus (T2DM) is a progressive condition often necessitating insulin therapy for sustained glycemic control, yet adherence to daily injections remains a significant challenge. While insulin glargine is effective, reducing injection frequency may improve compliance and outcomes. This study evaluates the efficacy and safety of once-weekly insulin icodec compared to once-daily insulin glargine U100. Methods: This systematic review and meta-analysis followed Cochrane and PRISMA guidelines. A comprehensive search across multiple databases identified randomized controlled trials (RCTs) comparing once-weekly insulin icodec with once-daily insulin glargine U100 in adults with T2DM. Eligible studies included adult participants and reported glycemic or safety outcomes. Data synthesis was performed using a random-effects model, with heterogeneity assessed via the I2 statistic. Results: Five RCTs comprising 2,019 participants met the inclusion criteria. Insulin icodec significantly reduced glycated hemoglobin (MD: āˆ’0.12; 95% CI: āˆ’0.20, āˆ’0.04; P = 0.003) and increased time in range (TIR; MD: 4.23; 95% CI: 2.20, 6.26; P < 0.0001) compared to insulin glargine. A modest increase in body weight was observed with insulin icodec, while safety profiles, including hypoglycemia rates and adverse events, were comparable between treatments. Conclusion: Insulin icodec provides a safe and effective alternative to once-daily insulin glargine for T2DM management, offering similar glycemic control with a once-weekly dosing regimen. The reduced injection burden may enhance adherence and treatment satisfaction, potentially improving long-term disease outcomes.